{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T06:59:15Z","timestamp":1763967555808,"version":"3.45.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Consejer\u00eda de Salud, Junta de Andaluc\u00eda","award":["PI-0077-2018"],"award-info":[{"award-number":["PI-0077-2018"]}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Subdirecci\u00f3n General de Redes y Centros de Investigaci\u00f3n Cooperativa"},{"name":"Ministerio de Ciencia"},{"name":"Innovaci\u00f3n y Universidades"},{"name":"Spanish Network for Research in Infectious Diseases","award":["REIPI RD16\/0016\/0001"],"award-info":[{"award-number":["REIPI RD16\/0016\/0001"]}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To establish a regional expert consensus on off-label indications for recently approved antimicrobials, based on a structured Delphi methodology, to support antimicrobial stewardship programs (ASPs) in Andalusia, Spain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>As part of the NEW_SAFE project, a modified Delphi process was employed involving 32 experts in Infectious Diseases and Intensive Care from 14 Andalusian hospitals. The process comprised three survey rounds evaluating off-label uses of eight drugs: ceftazidime-avibactam, ceftolozane-tazobactam, cefiderocol, ceftaroline, ceftobiprole, dalbavancin, tedizolid, and isavuconazole. Clinical scenarios were assessed under predefined conditions (efficacy\/safety, ecological impact, and cost) and circumstances (empirical versus targeted use, resistance prevalence, PK\/PD advantage).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The expert panel reached positive consensus (\u226580% agreement) on specific off-label targeted uses for all drugs except ceftobiprole. Empirical use was generally discouraged except under clear PK\/PD advantages or resistance profiles without alternatives. Notably, dalbavancin, ceftaroline, and ceftazidime-avibactam received multiple targeted-use endorsements, particularly for endocarditis, osteoarticular infections, and bacteraemia. Isavuconazole was recommended for rare fungal infections and in cases where it offers pharmacological advantages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This consensus supports the judicious off-label use of new antimicrobials in specific clinical scenarios where therapeutic gaps exist. The guidance prioritizes targeted treatment over empirical use, aligning with international ASP principles and WHO recommendations. These results provide a regional reference to optimize ASP initiatives focus on new antibiotic use while minimizing ecological impact and resistance development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jacamr\/dlaf184","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T11:56:06Z","timestamp":1759492566000},"source":"Crossref","is-referenced-by-count":0,"title":["How to use novel antimicrobials beyond official indications: an expert consensus"],"prefix":"10.1093","volume":"7","author":[{"given":"Pilar","family":"Retamar-Gentil","sequence":"first","affiliation":[{"name":"Unidad Cl\u00ednica de Enfermedades Infecciosas y Microbiolog\u00eda, Hospital Universitario Virgen Macarena, Instituto de Biomedicina de Sevilla (IBIS)\/CSIC, Departamentos de Medicina, Universidad de Sevilla , Sevilla ,","place":["Spain"]},{"name":"CIBERINFEC, Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Alegre-Albendea","sequence":"additional","affiliation":[{"name":"Unidad Cl\u00ednica de Enfermedades Infecciosas y Microbiolog\u00eda, Hospital Universitario Virgen Macarena, Instituto de Biomedicina de Sevilla (IBIS)\/CSIC, Departamentos de Medicina, Universidad de Sevilla , Sevilla ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"Valiente De Santis","sequence":"additional","affiliation":[{"name":"Unidad Cl\u00ednica de Enfermedades Infecciosas y Microbiolog\u00eda, Hospital Universitario de Valme, Instituto de Biomedicina de Sevilla (IBIS)\/CSIC, Departamentos de Medicina, Universidad de Sevilla , Sevilla ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Jos\u00e9","family":"Cast\u00f3n-Osorio","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Reina Sofia University Hospital, Maimonides Biomedical Research Institute of C\u00f3rdoba (IMIBIC) , Cordoba ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"M\u00e1rquez-G\u00f3mez","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Regional de M\u00e1laga , M\u00e1laga ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Enrique","family":"Corzo-Delgado","sequence":"additional","affiliation":[{"name":"Unidad Cl\u00ednica de Enfermedades Infecciosas y Microbiolog\u00eda, Hospital Universitario de Valme, Instituto de Biomedicina de Sevilla (IBIS)\/CSIC, Departamentos de Medicina, Universidad de Sevilla , Sevilla ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Praena-Segovia","sequence":"additional","affiliation":[{"name":"Clinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, Institute of Biomedicine of Seville (IBiS), Virgen del Roc\u00edo University Hospital, CSIC, University of Seville , Seville ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Herrero-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Unidad de Enfermedades Infecciosas y Microbiolog\u00eda, Complejo Hospitalario de Ja\u00e9n , Ja\u00e9n ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M \u00c1ngeles","family":"Esteban-Moreno","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Complejo Hospitalario Torrecardenas , Almeria, Andaluc\u00eda ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s","family":"Mart\u00edn-Aspas","sequence":"additional","affiliation":[{"name":"Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Facultad de Medicina, Hospital Universitario Puerta del Mar, Instituto de Investigaci\u00f3n e Innovaci\u00f3n en Ciencias Biom\u00e9dicas de C\u00e1diz (INiBICA), Universidad de C\u00e1diz , Cadiz ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Jim\u00e9nez-Aguilar","sequence":"additional","affiliation":[{"name":"Unidad de Enfermedades Infecciosas, Hospital Universitario de Puerto Real , C\u00e1diz ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Javier","family":"Mart\u00ednez-Marcos","sequence":"additional","affiliation":[{"name":"Unidad de Enfermedades Infecciosas, Hospital Universitario Juan Ram\u00f3n Jim\u00e9nez , Huelva ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvador","family":"L\u00f3pez-C\u00e1rdenas","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases and Clinical Microbiology, Jerez de la Frontera University Hospital , University of C\u00e1diz, Jerez De La Frontera, C\u00e1diz ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0544-4690","authenticated-orcid":false,"given":"Guillermo","family":"Ojeda-Burgos","sequence":"additional","affiliation":[{"name":"UGC de Enfermedades Infecciosas y Medicina Preventiva, IBIMA-Plataforma BIONAND, Hospital Universitario Virgen de la Victoria , M\u00e1laga ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Sadyrbaeva-Dolgova","sequence":"additional","affiliation":[{"name":"Hospital Universitario Virgen de las Nieves, Instituto de Investigaci\u00f3n Biosanitario de Granada , Granada ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Anguita-Santos","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, Hospital Universitario San Cecilio , Granada ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6732-9001","authenticated-orcid":false,"given":"Jes\u00fas","family":"Rodr\u00edguez Ba\u00f1o","sequence":"additional","affiliation":[{"name":"Unidad Cl\u00ednica de Enfermedades Infecciosas y Microbiolog\u00eda, Hospital Universitario Virgen Macarena, Instituto de Biomedicina de Sevilla (IBIS)\/CSIC, Departamentos de Medicina, Universidad de Sevilla , Sevilla ,","place":["Spain"]},{"name":"CIBERINFEC, Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaira R","family":"Palacios-Baena","sequence":"additional","affiliation":[{"name":"Unidad Cl\u00ednica de Enfermedades Infecciosas y Microbiolog\u00eda, Hospital Universitario Virgen Macarena, Instituto de Biomedicina de Sevilla (IBIS)\/CSIC, Departamentos de Medicina, Universidad de Sevilla , Sevilla ,","place":["Spain"]},{"name":"CIBERINFEC, Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"2025112401543205200_dlaf184-B1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s15010-019-01304-7","article-title":"Ceftaroline as salvage therapy for complicated MRSA bacteremia: case series and analysis","volume":"47","author":"Bhowmick","year":"2019","journal-title":"Infection"},{"key":"2025112401543205200_dlaf184-B2","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s40121-019-0247-0","article-title":"Dalbavancin use in vulnerable patients receiving outpatient parenteral antibiotic therapy for invasive gram-positive infections","volume":"8","author":"Bork","year":"2019","journal-title":"Infect Dis Ther"},{"key":"2025112401543205200_dlaf184-B3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ijid.2023.11.003","article-title":"Comparison of dalbavancin with standard of care in the management of infective endocarditis: efficacy, safety, and cost analysis","volume":"138","author":"Su\u00e1rez","year":"2024","journal-title":"Int J Infect Dis"},{"key":"2025112401543205200_dlaf184-B4","doi-asserted-by":"publisher","first-page":"5903","DOI":"10.1128\/AAC.00655-15","article-title":"Successful treatment of carbapenemase-producing pandrug-resistant Klebsiella pneumoniae bacteremia","volume":"59","author":"Camargo","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2025112401543205200_dlaf184-B5","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/FTD.0000000000000857","article-title":"Optimization of Aztreonam in combination with ceftazidime\/avibactam in a cystic fibrosis patient with chronic Stenotrophomonas maltophilia pneumonia using therapeutic drug monitoring: a case study","volume":"43","author":"Cowart","year":"2021","journal-title":"Ther Drug Monit"},{"key":"2025112401543205200_dlaf184-B6","doi-asserted-by":"publisher","first-page":"dlab188","DOI":"10.1093\/jacamr\/dlab188","article-title":"Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections","volume":"3","author":"Meschiari","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"2025112401543205200_dlaf184-B7","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.2147\/IDR.S421209","article-title":"Carbapenem-resistant Pseudomonas aeruginosa spondylodiscitis treated with ceftazidime-avibactam: a case report with literature review","volume":"16","author":"Danda","year":"2023","journal-title":"Infect Drug Resist"},{"key":"2025112401543205200_dlaf184-B8","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s15010-022-01834-7","article-title":"Successful ceftazidime-avibactam therapy in a patient with multidrug-resistant Pseudomonas aeruginosa infective endocarditis","volume":"50","author":"Lima","year":"2022","journal-title":"Infection"},{"key":"2025112401543205200_dlaf184-B9","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomized controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"2025112401543205200_dlaf184-B10","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2025112401543205200_dlaf184-B11","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/myc.12778","article-title":"Isavuconazole for treatment of rare invasive fungal diseases","volume":"61","author":"Cornely","year":"2018","journal-title":"Mycoses"},{"key":"2025112401543205200_dlaf184-B12","doi-asserted-by":"publisher","first-page":"22.e1","DOI":"10.1016\/j.eimc.2011.09.018","article-title":"Programs for optimizing the use of antibiotics (PROA) in Spanish hospitals: GEIH-SEIMC, SEFH and SEMPSPH consensus document","volume":"30","author":"Rodr\u00edguez-Ba\u00f1o","year":"2012","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"2025112401543205200_dlaf184-B13","doi-asserted-by":"publisher","first-page":"CD003543","DOI":"10.1002\/14651858.CD003543.pub4","article-title":"Interventions to improve antibiotic prescribing practices for hospital inpatients","volume":"2017","author":"Davey","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2025112401543205200_dlaf184-B14","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1080\/14787210.2018.1473079","article-title":"Ceftolozane-tazobactam resistance induced in vivo during the treatment of MDR Pseudomonas aeruginosa pneumonia","volume":"16","author":"Plant","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2025112401543205200_dlaf184-B15","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1093\/jac\/dky082","article-title":"In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime\/avibactam treatment","volume":"73","author":"Gaibani","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2025112401543205200_dlaf184-B16","doi-asserted-by":"publisher","first-page":"1244511","DOI":"10.3389\/fcimb.2023.1244511","article-title":"Dynamic evolution of ceftazidime-avibactam resistance due to interchanges between blaKPC-2 and blaKPC-145 during treatment of Klebsiella pneumoniae infection","volume":"13","author":"Chen","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"2025112401543205200_dlaf184-B17","doi-asserted-by":"publisher","first-page":"e035460","DOI":"10.1136\/bmjopen-2019-035460","article-title":"Quasiexperimental intervention study protocol to optimise the use of new antibiotics in Spain: the NEW_SAFE project","volume":"10","author":"Palacios-Baena","year":"2020","journal-title":"BMJ Open"},{"key":"2025112401543205200_dlaf184-B18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","article-title":"Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies","volume":"67","author":"Diamond","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"2025112401543205200_dlaf184-B19","volume-title":"The Rand\/UCLA Appropriateness Method User\u2019s Manual","author":"Fitch","year":"2001"},{"key":"2025112401543205200_dlaf184-B20","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2025112401543205200_dlaf184-B21","doi-asserted-by":"publisher","first-page":"ciae403","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025112401543205200_dlaf184-B22","doi-asserted-by":"publisher","first-page":"dlaa114","DOI":"10.1093\/jacamr\/dlaa114","article-title":"Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK","volume":"3","author":"Brown","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"2025112401543205200_dlaf184-B23","doi-asserted-by":"publisher","first-page":"1018158","DOI":"10.3389\/fphar.2022.1018158","article-title":"Predictors of inappropriate antimicrobial prescription: eight-year point prevalence surveys experience in a third level hospital in Spain","volume":"13","author":"N\u00fa\u00f1ez-N\u00fa\u00f1ez","year":"2022","journal-title":"Front Pharmacol"},{"key":"2025112401543205200_dlaf184-B24","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"2025112401543205200_dlaf184-B25"},{"issue":"Suppl 2","key":"2025112401543205200_dlaf184-B26","doi-asserted-by":"publisher","first-page":"ii2","DOI":"10.1093\/jac\/dkaa425","article-title":"Linking antimicrobial resistance surveillance to antibiotic policy in healthcare settings: the COMBACTE-Magnet EPI-Net COACH project","volume":"75","author":"Pezzani","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2025112401543205200_dlaf184-B27"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/7\/6\/dlaf184\/65486952\/dlaf184.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/7\/6\/dlaf184\/65486952\/dlaf184.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T06:54:39Z","timestamp":1763967279000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlaf184\/8340856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,10,30]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlaf184","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,10,30]]},"article-number":"dlaf184"}}